9:25 am Chairperson’s Opening Remarks
Improving Potency & Efficacy Through Design of Your ADC
9:30 am Strategies to Maximize the Effectiveness of Belantamab Mafodotin
Synopsis
- Leveraging antibody effector functions in combination with cytotoxic payloads
- Discussing manipulation of cell surface levels of target to maximize potency
- Examining the effect of DAR on efficacy
10:00 am Design Considerations for an Immunology Antibody Drug Conjugate (iADC)
Synopsis
- Outlining identification of the antibody target and parameters for selection and parameters of the optimal antibody
- Discussing considerations when choosing the payload MoA pairing for the antibody target
- Modifying of the ADC to both maximize the therapeutic index and afford the optimal physiochemical properties
10:30 am
Morning Break & Networking
Analyzing Approaches to Limit On-Target / Off-Tumor Toxicities
11:00 am A Critical Appraisal of Target Mediated & On-Target/Off-Tumor Toxicities of ADCs
Synopsis
- Understanding the critical importance of target expression and biology in maximizing the therapeutic index
- Discussing the challenges of predicting on target toxicities based on target expression on normal tissues
- Outlining the importance of the antibody quality, payload potency, linker and conjugation on target medicated toxicities
11:30 am Roundtable Discussion – Analyzing Approaches to Limit On-Target / Off-Tumor Toxicities of ADCs
Synopsis
- Following the previous talk, we will now look at how the community is thinking about on-target, off-tumor toxicities at the moment?
- Evaluating to what extent on-target, off-tumor toxicities impact go/no-go decisions during ADC development
- What challenges have people experienced in quantifying on-target, off-tumor toxicities?
12:10 pm Designing Site-Specific ADCs to Maximize Target-Mediated Payload Delivery
Synopsis
- Outlining HT identification of bioconjugation site from ADC libraries
- Discovering glycosylated variants amenable to bTGase conjugation
- Discussing characterization of thermal and metabolic stabilities of site-specific ADCs to guide construct design for maximizing target-dependent delivery
12:40 pm
Lunch & Networking
Harnessing Bioinformatics for Improved Target Selection
1:40 pm Utilizing Computational Proteomics for ADC Target Discovery
2:10 pm Quantitative Proteomics Approaches for ADC Target Characterization
Synopsis
- Discussing DIA-MS peptide level quantification for epitope and isoform precision
- Explore how to quantify cell surface protein dynamics using pulsed SILAC labeling
- Examine the profiling of protein drug interactions (PDIs) Using IP-MS
2:40 pm Roundtable Discussion – How Can Assays & Screening Technologies Be Improved to Better Understand ADC-Target Interactions In Vitro to Develop ADCs With a Wider Therapeutic Index?
Synopsis
- Discussing approaches to make cell lines more representative of tumor target expression
- How can assays be improved to better understand internalization?
- Outlining approaches to developing high-throughput assays for quicker and improved screening of potential targets